Karyopharm Therapeutics (KPTI) Net Cash Flow (2012 - 2025)
Karyopharm Therapeutics' (KPTI) quarterly Net Cash Flow came in at $22.9 million in Q4 2025, up 321.27% YoY from $5.4 million in Q4 2024, and up 2267.2% on a QoQ basis from -$1.1 million in Q3 2025.
Karyopharm Therapeutics (KPTI) Net Cash Flow (2012 - 2025) Analysis & Trends
Karyopharm Therapeutics (KPTI) has 14 years of Net Cash Flow data on file, last reported at $22.9 million in Q4 2025.
- Quarterly Net Cash Flow rose 321.27% year-over-year to $22.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$2.3 million (up 92.66% YoY) and the FY2025 annual result came in at -$1.9 million, down 120.17% from the prior year.
- Net Cash Flow advanced to $22.9 million in Q4 2025, from -$1.1 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $63.7 million in Q4 2022 to a low of -$70.4 million in Q2 2022.
- A 5-year average of -$3.4 million and a median of -$3.1 million in 2021 frame the typical range for Net Cash Flow.
- Annual changes were most pronounced in 2021 — Net Cash Flow soared 1107.8% — and 2022, when it sank 4458.21%.
- Tracing KPTI's Net Cash Flow over 5 years: stood at $57.1 million in 2021, then climbed by 11.48% to $63.7 million in 2022, then tumbled by 86.62% to $8.5 million in 2023, then plunged by 221.25% to -$10.3 million in 2024, then surged by 321.27% to $22.9 million in 2025.
- The last three Net Cash Flow figures came in at $22.9 million (Q4 2025), -$1.1 million (Q3 2025), and -$412000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Karyopharm Therapeutics | 56.72 Mn | 56.72 Mn | 32.35 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 22.86 Mn |
| Dec 31, 2025 | 22.86 Mn |
| Sep 30, 2025 | -1.06 Mn |
| Sep 30, 2025 | -1.06 Mn |
| Jun 30, 2025 | -412,000.00 |
| Jun 30, 2025 | -412,000.00 |
| Mar 31, 2025 | -23.70 Mn |
| Mar 31, 2025 | -23.70 Mn |
| Dec 31, 2024 | -10.33 Mn |
| Dec 31, 2024 | -10.33 Mn |
| Sep 30, 2024 | -11.98 Mn |
| Sep 30, 2024 | -11.98 Mn |
| Jun 30, 2024 | 12.76 Mn |
| Jun 30, 2024 | 12.76 Mn |
| Mar 31, 2024 | -21.79 Mn |
| Mar 31, 2024 | -21.79 Mn |
| Dec 31, 2023 | 8.52 Mn |
| Dec 31, 2023 | 8.52 Mn |
| Sep 30, 2023 | -37.22 Mn |
| Sep 30, 2023 | -37.22 Mn |